10-Q: Lunai Bioworks Reports Q1 Profit Amid Restructuring, Legal Woes

Lunai Bioworks Inc. reported a net income of $2.82 million for the quarter ended September 30, 2025, a significant improvement from a prior-year loss, driven by one-time gains and reduced operating expenses, despite ongoing legal challenges and a 'going concern' warning.

Summary

• Lunai Bioworks Inc. (formerly Renovaro Inc.) reported a net income of $2,819,021 for the three months ended September 30, 2025, a substantial improvement from a net loss of $44,212,036 in the same period last year.
• Total operating expenses decreased by 94% to $3,308,360, primarily due to the absence of a $47,614,729 goodwill impairment charge recorded in the prior year.
• General and administrative expenses decreased by 55% to $2,410,516, and research and development expenses decreased by 94% to $24,407.
• The company recognized a $12,019,227 gain from the bankruptcy of its indirect subsidiary, Gedi Cube B.V., which was deconsolidated on September 2, 2025.
• A loss on extinguishment of debt of $6,329,592 was incurred due to the exchange of $9.7 million in secured promissory notes for $16.1 million in new convertible notes, which were immediately converted into 5.36 million shares of common stock.
• Cash and cash equivalents increased to $624,808 as of September 30, 2025, from $92,700 at June 30, 2025.
• The working capital deficit improved to $18,922,114 from $28,109,502 at June 30, 2025.
• Total liabilities decreased by $9,579,244 to $20,001,437 as of September 30, 2025.
• The company completed a 1-for-10 reverse stock split, effective September 29, 2025, with common stock trading on a split-adjusted basis on Nasdaq.
• Lunai Bioworks Inc. acquired BioSymetrics, Inc. on April 8, 2025, for approximately $6 million, adding goodwill, software, and trademarks related to an AI-driven precision medicine platform.
• Management identified a material weakness in internal controls over financial reporting due to inadequate resources to address complex accounting matters.
• The company faces numerous ongoing legal proceedings, including securities class action and shareholder derivative lawsuits, and a company-initiated lawsuit alleging fraud against former associates, which was dismissed on November 7, 2025.

Sentiment

Score: 3

Explanation: While the company reported a net income and reduced operating expenses, these positives are largely driven by one-time gains and the absence of prior-year impairments. The company remains pre-revenue, carries a substantial accumulated deficit, and faces a 'going concern' warning. Extensive and complex legal proceedings, including a dismissed fraud complaint against former associates and a material weakness in internal controls, indicate significant operational and governance risks. The extremely low R&D spending for a biotech company is also a concern.

Positives

• Reported a net income of $2.82 million for the quarter, a significant turnaround from a $44.21 million net loss in the prior year.
• Total operating expenses decreased by 94%, primarily due to the absence of a large goodwill impairment charge from the previous period.
• General and administrative expenses decreased by 55% ($2.89 million reduction), indicating cost control efforts.
• Cash balance increased significantly to $624,808 from $92,700 at the end of the previous fiscal year.
• Working capital deficit improved by approximately $9.19 million.
• Total liabilities decreased by $9.58 million, improving the balance sheet structure.
• Successfully restructured $9.7 million in secured promissory notes into $16.1 million in convertible notes, which were then converted into 5.36 million shares of common stock, reducing debt obligations.
• Preliminary approval was granted for the settlement of the Securities Class Action Litigation (Chow Action), potentially resolving a significant legal overhang.
• The acquisition of BioSymetrics, Inc. strengthens the company's AI-driven precision medicine, diagnostics, and biodefense platform.

Negatives

• The company remains pre-revenue and pre-clinical, with no anticipated revenues until therapies or products are approved for marketing and sale.
• Incurred a $6,329,592 loss on extinguishment of debt as part of the debt restructuring.
• The bankruptcy of Gedi Cube B.V., an indirect subsidiary, indicates a failed venture, despite resulting in a one-time accounting gain.
• The company has an accumulated deficit of $507,643,549 and a working capital deficit of $18,922,114, raising substantial doubt about its ability to continue as a going concern.
• Identified a material weakness in internal controls over financial reporting due to inadequate resources.
• Research and development expenses are extremely low at $24,407 for the quarter, which is concerning for a biotechnology company developing multiple product candidates.
• Incurred a long-lived asset impairment of $831,915 due to no longer using certain assets.
• The company's lawsuit alleging fraud against former associates (Serhat Gmrkc, William Anderson Wittekind, G Tech Bio, etc.) was dismissed by the court on November 7, 2025, which is a significant setback.

Risks

• Substantial recurring losses from continuing operations and dependence on additional financing to fund operations.
• No assurance that additional funding will be available on reasonable terms, or at all, which could lead to material reduction or suspension of operations or bankruptcy.
• Equity financing transactions could result in significant additional dilution to existing stockholders.
• The company's ability to continue as a going concern is in substantial doubt, and financial statements do not include adjustments for potential inability to continue in existence.
• Adverse outcomes in ongoing legal or regulatory proceedings could materially affect liquidity and financial position.
• A material weakness exists in internal controls over financial reporting due to inadequate resources to address complex accounting matters.
• The company is pre-revenue and does not anticipate earning revenues until therapies or products are approved for marketing and sale, with no guarantee a market will develop.
• Forward-looking statements are based on assumptions that may prove inaccurate, leading to actual results differing materially.

Future Outlook

Management plans to secure additional funding through equity or debt financing to satisfy existing and future obligations, support product commercialization, conduct clinical and regulatory work for product candidates, and build working capital reserves. The company is streamlining its organization to focus on the development and validation of its AI-driven neurology and oncology diagnostics and therapeutic development platform. No revenues are anticipated until therapies or products receive marketing approval.

Management Comments

• Management has reduced overhead and administrative costs by streamlining the organization to focus around the development, validation, and commercialization of its AI-driven neurology and oncology diagnostics and therapeutic development platform.
• The Company has tailored its workforce to focus on these activities.
• The Company intends to secure additional required funding through equity or debt financing.
• We are a pre-revenue, pre-clinical biotechnology and artificial intelligence driven healthcare technology company. We have never generated revenues and have incurred losses since inception. We do not anticipate earning any revenues until our therapies or products are approved for marketing and sale.
• The deficiency [in disclosure controls] is attributed to the Company not having adequate resources to address complex accounting matters. This control deficiency will be monitored, and attention will be given to this matter as we grow.

Industry Context

Lunai Bioworks operates in the highly competitive and capital-intensive biotechnology sector, focusing on AI-driven precision medicine, diagnostics, and biodefense. Its strategic shift towards allogeneic cell and gene therapies for oncology (pancreatic, triple-negative breast cancer) and infectious diseases (HIV), coupled with the BioSymetrics acquisition for multimodal data integration and machine learning, aligns with cutting-edge trends in personalized medicine and drug discovery. However, as a pre-revenue, pre-clinical company, it faces significant challenges common to early-stage biotech firms, including substantial funding requirements and regulatory hurdles, compounded by extensive legal issues.

Comparison to Industry Standards

• The company's pre-revenue status and significant accumulated deficit are typical for early-stage biotechnology firms, but the scale of its legal challenges and internal control weaknesses are notably higher than industry averages for companies at a similar development stage.
• The reported research and development expenses of $24,407 for the quarter are extremely low for a biotechnology company actively developing multiple therapeutic candidates, suggesting either minimal internal R&D activity or a heavily outsourced model not fully detailed, which could be a concern compared to peers investing heavily in pipeline development.
• The focus on AI-driven platforms and allogeneic cell/gene therapies aligns with innovative trends in oncology and infectious disease, positioning the company in a high-growth segment, but specific benchmarks for success or comparative efficacy against established or emerging industry players are not provided in the filing.

Management Changes

Corporate Governance

Legal Proceedings

• Securities Class Action Litigation (Chow Action): A settlement stipulation has been signed, and the court granted preliminary approval of the settlement on August 18, 2025, potentially resolving claims of false and misleading statements.
• Federal Derivative Litigation (Koenig Matter, Solak Matter): These shareholder derivative actions, alleging breach of fiduciary duty and other claims, are stayed pending resolution of the Securities Class Action Litigation. A motion for preliminary approval of a settlement for these matters was filed on November 3, 2025.
• State Derivative Litigation (Midler Matter): Similar to the federal derivative actions, this matter is stayed and a motion for preliminary approval of a settlement was filed on November 3, 2025.
• Company's Complaint against Serhat Gmrkc, William Anderson Wittekind, G Tech Bio, SG & AW Holdings, LLC, and SRI: The company alleges fraud and misrepresentation of study results, claiming approximately $25 million in damages. The trial, originally set for March 3, 2025, has been reset to November 30, 2026. Defendants have filed a cross-complaint seeking termination of license agreements.
• Weird Science LLC et al. v. Company: Plaintiffs allege breaches of an Investor Rights Agreement (registration rights), fraud, and other torts. The court dismissed some claims but denied dismissal for others. An appeal is pending regarding the dismissal of a related derivative complaint.
• Company's Suit against Weird Science, Gumrukcu, Wittekind, and certain trusts: The company alleged fraudulent concealment of a murder-for-hire scheme to induce a merger. The court granted the defendants' motion to dismiss the complaint on November 7, 2025.
• Lunai v. Predictive Oncology, Inc. (POAI): Lunai commenced an action claiming POAI breached a letter agreement to acquire POAI, seeking specific performance or money damages. The action is currently held in abeyance for settlement negotiations.

Related Party Transactions

• Accrued $384,949 of compensation related expenses for the company's former Chief Executive Officer, Mark Dybul.
• Avram Miller, a former member of the Board of Directors, forfeited 83,333 shares of common stock and was granted an option to purchase 97,826 shares.
• Paseco ApS, a Danish entity controlled by a shareholder, and Laksya Ventures Inc. were involved in bridge loans and the conversion of promissory notes into common stock.
• RS Bio ApS, a Danish entity controlled by a shareholder, and Rene Sindlev (assignee of RS Bio's rights) were involved in promissory notes that were later converted into common stock.
• G Tech Bio, LLC and G Health Research Foundation (SRI), controlled by Anderson Wittekind (a stockholder), are parties to various license agreements and are defendants in the company's fraud complaint and plaintiffs in a cross-complaint.

Stakeholder Impact

• Shareholders: Experienced significant dilution from debt-to-equity conversions and a 1-for-10 reverse stock split. Ongoing legal uncertainties and the 'going concern' warning pose substantial risks to investment value. Potential benefit from the settlement of the securities class action.
• Employees: The company has streamlined its organization and tailored its workforce, which may imply job reductions or reassignments, particularly with the bankruptcy of Gedi Cube B.V.
• Creditors: Debt restructuring through conversion of notes into equity has altered the company's creditor landscape, with some former noteholders becoming shareholders.
• Customers/Partners: As a pre-revenue company, direct customer impact is minimal. However, the acquisition of BioSymetrics could lead to future partnerships and offerings in AI-driven medicine. Legal disputes with former partners (G Tech, SRI) could deter future collaborations.

Next Steps

• Secure additional required funding through equity or debt financing to support operations.
• Satisfy existing and future obligations and liabilities and address working capital needs.
• Support commercialization efforts for potential products.
• Conduct clinical and regulatory work to advance product candidates.
• Begin building working capital reserves.
• Monitor and address the identified material weakness in disclosure controls and procedures.
• Continue to vigorously defend against and pursue various ongoing legal proceedings.
• Prepare for the rescheduled trial in the Company's complaint against Serhat Gmrkc et al. on November 30, 2026.
• Await final approval of the settlement in the Securities Class Action Litigation (Chow Action).
• Await preliminary approval of the Koenig-Solak-Midler Settlement.

Key Dates

Recommendation

Despite reporting a net income for the quarter, this was primarily due to one-time gains from a subsidiary's bankruptcy and the absence of prior-year goodwill impairment. The company remains pre-revenue, carries a substantial accumulated deficit, and has a significant working capital deficit, leading to a 'going concern' warning. The extensive and complex legal landscape, including multiple shareholder derivative suits and the recent dismissal of the company's own fraud complaint against former associates, indicates severe corporate governance and operational risks. The identified material weakness in internal controls further undermines investor confidence. While debt restructuring has occurred, the continuous need for capital raises and potential future dilution, combined with extremely low R&D spending for a biotech company, suggests a highly speculative and risky investment profile with significant downside potential.

Keywords

Biotechnology, AI-driven medicine, Precision medicine, Oncology, HIV treatment, Cell therapy, Gene therapy, SEC filing, 10-Q, Financial results, Going concern, Legal proceedings, Reverse stock split, BioSymetrics acquisition, Debt restructuring